• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

腹膜透析患者中肾性贫血及对促红细胞生成素类似物反应低下对残余肾功能的影响

Renal anemia and hyporesponsiveness to ESA for preservation of residual kidney function in patients undergoing peritoneal dialysis.

作者信息

Imaizumi Takahiro, Hasegawa Takeshi, Kosugi Takaaki, Nishiwaki Hiroki, Abe Masanori, Hanafusa Norio, Honda Hirokazu, Tsuruya Kazuhiko, Ito Yasuhiko, Kuragano Takahiro

机构信息

Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan.

Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, 466-8550, Japan.

出版信息

Sci Rep. 2025 Jan 21;15(1):2689. doi: 10.1038/s41598-025-87456-z.

DOI:10.1038/s41598-025-87456-z
PMID:39838061
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11751488/
Abstract

Preservation of residual kidney function (RKF) is important in patients undergoing peritoneal dialysis (PD). We aimed to examine the association between anemia management and residual urine output using data from a nationwide survey of dialysis patients. After excluding patients with anuria at baseline from the Total cohort of 2,712, 659 of 1,640 patients developed anuria during a median follow-up of 2.5 (interquartile range: 1.5-4.2) years. Urine volume decreased more rapidly as hemoglobin decreased or as the erythropoiesis-stimulating agent (ESA) resistance index (ERI) increased. The hazard ratios with 95% confidence intervals for the development of anuria, defined as residual urine volume ≤ 100 mL/day, were 1.65 (1.20-2.27), 1.39 (1.08-1.77), and 1.32 (1.07-1.63) for hemoglobin levels of < 9.0, 9.0-9.9, and 10.0-10.9 g/dL compared with 11.0-11.9 g/dL, and 1.35 (1.10-1.66) and 1.41 (1.14-1.73) for the second and third tertiles of ERI compared with the first tertile. In conclusion, patients with a low hemoglobin level or a high ERI were more likely to experience a decline in residual urine output and to develop anuria. Further studies are needed to investigate the effects of interventions that could improve renal anemia and/or ESA hyporesponsiveness on RKF preservation.

摘要

对于接受腹膜透析(PD)的患者而言,保留残余肾功能(RKF)至关重要。我们旨在利用一项针对透析患者的全国性调查数据,研究贫血管理与残余尿量之间的关联。在2712名总队列患者中,排除基线时无尿的患者后,1640名患者中有659名在中位随访2.5年(四分位间距:1.5 - 4.2年)期间出现无尿。随着血红蛋白降低或促红细胞生成素(ESA)抵抗指数(ERI)升高,尿量下降更快。对于定义为残余尿量≤100 mL/天的无尿发生情况,血红蛋白水平<9.0、9.0 - 9.9、10.0 - 10.9 g/dL与11.0 - 11.9 g/dL相比,其95%置信区间的风险比分别为1.65(1.20 - 2.27)、1.39(1.08 - 1.77)和1.32(1.07 - 1.63);ERI的第二和第三三分位数与第一三分位数相比,风险比分别为1.35(1.10 - 1.66)和1.41(1.14 - 1.73)。总之,血红蛋白水平低或ERI高的患者更有可能出现残余尿量下降并发展为无尿。需要进一步研究以调查可改善肾性贫血和/或ESA低反应性的干预措施对保留RKF的影响。

相似文献

1
Renal anemia and hyporesponsiveness to ESA for preservation of residual kidney function in patients undergoing peritoneal dialysis.腹膜透析患者中肾性贫血及对促红细胞生成素类似物反应低下对残余肾功能的影响
Sci Rep. 2025 Jan 21;15(1):2689. doi: 10.1038/s41598-025-87456-z.
2
Hyporesponsiveness to Erythropoiesis-Stimulating Agents in Dialysis-Dependent Patients with Anaemia of Chronic Kidney Disease: A Retrospective Observational Study.依赖透析的慢性肾脏病贫血患者对促红细胞生成素刺激剂反应低下:一项回顾性观察研究
Adv Ther. 2025 Jan;42(1):471-489. doi: 10.1007/s12325-024-03015-4. Epub 2024 Nov 25.
3
Changes in erythropoiesis-stimulating agent responsiveness after transfer to combined therapy with peritoneal dialysis and hemodialysis for patients on peritoneal dialysis: A prospective multicenter study in Japan.腹膜透析转为腹膜透析和血液透析联合治疗后红细胞生成刺激剂反应性的变化:日本一项前瞻性多中心研究。
Ther Apher Dial. 2023 Aug;27(4):735-741. doi: 10.1111/1744-9987.13981. Epub 2023 Mar 22.
4
Erythropoietin Resistance Index and the Affecting Factors in Children with Peritoneal Dialysis.红细胞生成素抵抗指数及其对腹膜透析患儿的影响因素。
Blood Purif. 2021;50(6):942-951. doi: 10.1159/000514060. Epub 2021 Mar 30.
5
Association of Erythropoietin-Stimulating Agent Responsiveness with Mortality in Hemodialysis and Peritoneal Dialysis Patients.促红细胞生成素刺激剂反应性与血液透析和腹膜透析患者死亡率的关联
PLoS One. 2015 Nov 20;10(11):e0143348. doi: 10.1371/journal.pone.0143348. eCollection 2015.
6
Erythropoietin Hyporesponsiveness in Dialysis Patients: Possible Role of Statins.透析患者中的促红细胞生成素低反应性:他汀类药物的潜在作用。
Am J Nephrol. 2017;46(1):11-17. doi: 10.1159/000477217. Epub 2017 Jun 1.
7
Role of residual renal function in phosphate control and anemia management in chronic hemodialysis patients.残余肾功能在慢性血液透析患者的磷控制和贫血管理中的作用。
Clin J Am Soc Nephrol. 2011 Feb;6(2):281-9. doi: 10.2215/CJN.04480510. Epub 2010 Oct 28.
8
Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).慢性肾脏病合并肾性贫血患者观察性临床研究的原理与设计:对促红细胞生成素刺激剂反应低下的贫血患者的肾脏预后,达贝泊汀α(BRIGHTEN试验)
Clin Exp Nephrol. 2018 Feb;22(1):78-84. doi: 10.1007/s10157-017-1427-4. Epub 2017 Jun 28.
9
Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D).全球达普司他透析研究(ASCEND-D)中红细胞生成刺激剂低反应性的区域差异。
Am J Nephrol. 2023;54(1-2):1-13. doi: 10.1159/000528696. Epub 2023 Feb 7.
10
Spectrum and Burden of Erythropoiesis-Stimulating Agent Hyporesponsiveness Among Contemporary Hemodialysis Patients.当代血液透析患者中红细胞生成刺激剂低反应性的范围和负担。
Am J Kidney Dis. 2016 Nov;68(5):763-771. doi: 10.1053/j.ajkd.2016.05.031. Epub 2016 Aug 12.

本文引用的文献

1
Management of anaemia and prognosis of patients undergoing maintenance peritoneal dialysis: A nationwide cohort study.维持性腹膜透析患者贫血的管理与预后:一项全国性队列研究。
Perit Dial Int. 2025 Jul;45(4):214-223. doi: 10.1177/08968608241244995. Epub 2024 Jun 3.
2
Associations of calcium, phosphate and intact parathyroid hormone levels with mortality, residual kidney function and technical failure among patients on peritoneal dialysis.腹膜透析患者中钙、磷和完整甲状旁腺激素水平与死亡率、残余肾功能及技术失败的相关性
Clin Kidney J. 2023 Sep 7;16(11):1957-1964. doi: 10.1093/ckj/sfad223. eCollection 2023 Nov.
3
A Review of Residual Kidney Function in Peritoneal Dialysis Patients.
腹膜透析患者残余肾功能综述
Indian J Nephrol. 2023 Jul-Aug;33(4):239-246. doi: 10.4103/ijn.ijn_242_23. Epub 2023 Aug 16.
4
Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study.非透析依赖性慢性肾脏病患者对红细胞生成刺激剂反应低下:BRIGHTEN 研究。
PLoS One. 2022 Nov 29;17(11):e0277921. doi: 10.1371/journal.pone.0277921. eCollection 2022.
5
Urine volume as an estimator of residual renal clearance and urinary removal of solutes in patients undergoing peritoneal dialysis.尿容量作为腹膜透析患者残余肾功能和溶质尿清除率的估计值。
Sci Rep. 2022 Nov 5;12(1):18755. doi: 10.1038/s41598-022-23093-0.
6
Erythropoietin-Stimulating Agent Hyporesponsiveness in Patients Living with Chronic Kidney Disease.慢性肾脏病患者对促红细胞生成素刺激剂的低反应性
Kidney Dis (Basel). 2022 Jan 14;8(2):103-114. doi: 10.1159/000521162. eCollection 2022 Mar.
7
Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis.罗沙司他对新进入腹膜透析患者贫血及残余肾功能的疗效。
Ren Fail. 2022 Dec;44(1):529-540. doi: 10.1080/0886022X.2022.2050754.
8
ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment.国际腹膜透析学会(ISPD)腹膜炎指南建议:2022年预防与治疗更新版
Perit Dial Int. 2022 Mar;42(2):110-153. doi: 10.1177/08968608221080586.
9
Managing Anemia across the Stages of Kidney Disease in Those Hyporesponsive to Erythropoiesis-Stimulating Agents.管理对红细胞生成刺激剂低反应性的慢性肾脏病各期患者的贫血
Am J Nephrol. 2021;52(6):450-466. doi: 10.1159/000516901. Epub 2021 Jul 19.
10
CERA conversion to darbepoetin alfa in 154 hemodialysis patients.154 例血液透析患者由 CERA 转换为达贝泊汀α。
Int Urol Nephrol. 2020 Oct;52(10):1979-1985. doi: 10.1007/s11255-020-02569-w. Epub 2020 Jul 28.